Colorectal cancer is a significant health concern in China, with high incidence and mortality rates. Research indicates that screening and early diagnosis, especially for high-risk groups, can significantly improve early detection and reduce mortality.

Pillar Biosciences said Monday that China's National Medical Products Administration has granted commercial approval for its OncoReveal Dx Colon Cancer Assay.

On August 5, 2021, Pillar Biosciences announced the FDA has given PMA to its oncoReveal™ Dx Lung and Colon Cancer Assay, an NGS tissue-based companion diagnostic test for the detection of somatic mutations in DNA derived from non-small cell lung cancer (NSCLC) and colorectal (CRC) cancer tumors